|
Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) |
|
Madrigal Pharmaceuticals Inc
MDGL's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Madrigal Pharmaceuticals Inc growth rates, revenue grew
in III. Quarter 2024 from the same quarter a year ago.
Ranking at No. 5
Major Pharmaceutical Preparations industry recorded
growth of revenues by 9.75 %
Madrigal Pharmaceuticals Inc net loss increased from $-99 millions, to $-107 millions in III. Quarter 2024,
• More on MDGL's Growth
|
|
Madrigal Pharmaceuticals Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 40.63 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 92.9.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.22.
• More on MDGL's Valuation
|
|
|
|
|
Madrigal Pharmaceuticals Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 40.63 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 92.9.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.22.
Madrigal Pharmaceuticals Inc Price to Book Ratio is at 9.18 lower than Industry Avg. of 431.27. and higher than S&P 500 Avg. of 0.01
• More on MDGL's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com